塞德斯医疗公布Cdx-622一期临床试验的初步积极结果,显示该药物具有良好的安全性和药代动力学特征,并且能够有效持续抑制肥大细胞。
塞德斯医疗公布Cdx-622一期临床试验的初步积极结果,显示该药物具有良好的安全性和药代动力学特征,并且能够有效持续抑制肥大细胞。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.